ReviewPediatric nephrology (Berlin, Germany)2019
Measurement of iron status in chronic kidney disease.
Review in Pediatric nephrology (Berlin, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Recent Advances in Research on Iron Metabolism, Ferritin, and Hepcidin.International journal of molecular sciences · 2026Pooled it
- GFR is a Key Determinant of Red Blood Cell Survival in Anemia Associated With Progressive CKD.Kidney international reports · 2025Article
- The Correlation between Reticulocyte Hemoglobin Equivalent (RET-He), Iron Status, and Erythrocyte Indices in Chronic Kidney Disease Patients at Prof. Dr. R.D. Kandou Manado Hospital.International journal of hematology-oncology and stem cell research · 2025Article
- The association between transferrin saturation and all-cause mortality in chronic kidney disease: findings from Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease.Kidney research and clinical practice · 2024Article
- Role of Nutrients in Pediatric Non-Dialysis Chronic Kidney Disease: From Pathogenesis to Correct Supplementation.Biomedicines · 2024Review
- Association between iron status markers and kidney outcome in patients with chronic kidney disease.Scientific reports · 2023Article
- GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease.Italian journal of pediatrics · 2023Article
- Association between susceptibility value and cerebral blood flow in the bilateral putamen in patients undergoing hemodialysis.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
- Benefits and risks of essential trace elements in chronic kidney disease: a narrative review.Annals of translational medicine · 2022Review
- Biomarkers of iron metabolism in chronic kidney disease.International urology and nephrology · 2021Review
- Iron metabolism and management: focus on chronic kidney disease.Kidney international supplements · 2021Article
- Urine hemojuvelin in cats with naturally occurring kidney disease.Journal of veterinary internal medicine · 2020Article
- Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation.Disease markers · 2020Article
- The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia.International journal of molecular sciences · 2019Review
- Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.Nutrients · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anemia is a common complication of chronic kidney disease (CKD) in children, and dysregulation of iron homeostasis plays a central role in its pathogenesis. Optimizing iron status is a prerequisite for effective treatment of anemia. Insufficient iron can lead to inappropriate escalation of the erythropoiesis-stimulating agent (ESA) dose, which is associated with adverse outcomes. Excess iron supplementation also has negative sequelae including free radical tissue damage and increased risk of systemic infection. Notwithstanding the importance of optimizing bioavailable iron for erythropoiesis for children with advanced CKD, achieving this remains challenging for pediatric nephrologists due to the historical lack of practical and robust measures of iron status. In recent years, novel techniques have come to the fore to facilitate accurate and practical assessment of iron balance. These measures are the focus of this review, with emphasis on their relevance to the pediatric CKD population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.